Significance of Durable Responses in DeLLphi-301 Trial
Joshua K. Sabari, MD, discusses how, despite the relatively small numbers of CRs and PRs in the DeLLphi-301 trial, the DOR to tarlatamab (exceeding 6 months in 59% of patients and more than 9 months in 29%) is promising, particularly considering that more than 50% of responders maintained their response at the data cutoff, indicating potential long-term benefits in this treatment setting.
EP: 1.Clinical Impressions and Therapy Goals
EP: 2.Considerations for Extended Chemoimmunotherapy
EP: 3.Prophylactic Cranial Irradiation Considerations
EP: 4.Mechanism of Action of BiTE Immunotherapy
EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes
Now Viewing
EP: 6.Significance of Durable Responses in DeLLphi-301 Trial
Video content above is prompted by the following:
Despite the relatively small numbers of CRs and PRs (n = 68) in DeLLphi-301, please discuss your opinion on the DOR to tarlatamab at greater than 6 months (59%) and at greater than 9 months (29%), as well as the ongoing response at data cutoff (> 50% [n = 38]) in the 2 treatment groups?
Recent Videos
Related Content
